iProgen Biotech is at the forefront of developing next-generation antibody drug conjugates (ADCs) with a focus on innovative delivery technologies. Central to their approach is the proprietary Smart Antibodies™ technology, which enhances the delivery and internalization of therapeutic agents. This technology allows for the use of a diverse range of payloads, including oligonucleotides, peptides, PROTACs, and even sugars, thereby broadening the therapeutic applications of ADCs beyond traditional oncology treatments. iProgen's commitment to innovation is reflected in their extensive research collaborations and a robust portfolio of patents and scientific publications, positioning them as leaders in the biotechnology sector.

The company is actively engaged in various research projects aimed at exploring the therapeutic potential of their ADC technologies across multiple indications, including oncology, neurodegenerative diseases, and osteoporosis. Their collaborations with academic institutions and industry partners facilitate the development of novel therapeutic strategies, such as antibody-oligo conjugates and antibody-PROTAC technologies. By continuously pushing the boundaries of scientific research and fostering partnerships, iProgen aims to unlock new treatment modalities that address unmet medical needs, thereby revolutionizing the landscape of biotherapeutics.

Canada

We’re at the forefront of next-generation antibody drug conjugate discovery, thanks to our innovative, in-house developed Smart AntibodiesTM delivery technologies and utilization of the next-generation smart Payloads such as oligonucleotides, PROTAC, and peptides. Our mission? To unlock the vast therapeutic potential of the antibody drug conjugate modality. To achieve this, we’re engaged in expansive global collaborations with leaders in therapeutic research.

iProgen Biotech

Company Details